Autonomic regulation of heart rate is largely mediated by the effect of cAMP on the pacemaker current I f , driven by hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. cAMP 2 enhances HCN open probability by binding to the CNBD (cyclic nucleotide binding domain). The Clinker transmits the cAMP-induced conformational change from the CNBD to the pore and is thus considered a passive element in the opening transition. Here we report the finding of an allosteric binding site in the C-linker of HCN4 that implies a regulatory function of this domain. By structural and functional analysis we show that cyclic dinucleotides, an emerging class of second messengers in mammals, bind to this C-linker pocket (CLP) and antagonize cAMP regulation of HCN4 channels. Accordingly, cyclic dinucleotides prevent cAMP regulation of I f in sinoatrial-node myocytes, reducing heart rate by 30%. The same effect is attained by Compound 11, a molecule selected by virtual docking to the CLP. Occupancy of the CLP hence constitutes an efficient mechanism to prevent -adrenergic stimulation on I f . Our results highlight the regulative role of the C-linker in HCN4 and identify an isoform-specific drug target within the HCN family. Furthermore, these data extend the signaling scope of cyclic dinucleotides in mammals, beyond their first reported role in innate immune system.
Introduction
The "funny" current (I f ) of cardiac pacemaker myocytes is an inward current activated by hyperpolarization of membrane voltage and controlled by intracellular cAMP 1 . Being activated and inhibited by -adrenergic and muscarinic M2 receptor stimulation, respectively, I f represents a basic physiological mechanism mediating autonomic regulation of heart rate and constitutes an ideal target for the pharmacological control of cardiac activity. The molecular determinants of I f are the Hyperpolarization-activated cAMP-gated (HCN) channels 2,3 . In these proteins, the transmembrane pore is connected at the N terminus to a voltage sensor domain and at the C-terminus to a cytosolic cyclic-nucleotide-binding domain (CNBD). The C-linker, anhelix folded domain of 90 amino acids, connects the CNBD to the pore. Structural studies showed that the cytosolic C-terminal fragment (C-linker + CNBD) assembles as a 4-fold symmetric tetramer in which the primary subunit interactions are provided by the linkers. The C-linkers form a ring in which the first two helices of one subunit (A' and B') form a helix-turn-helix motif that rests as an "elbow" on the "shoulder"
formed by the second two helices, C' and D', of the neighboring subunit 4 . Enhancement of channel open probability by cAMP reflects the transition from the cAMP-unbound to the bound conformation of the CNBD that induces a centrifugal rearrangement of the C-linkers with the shoulders twisting away from the elbows 5 . This movement in turn stabilizes the open conformation of the pore. Given the critical role of the Clinker in HCN channel modulation by ligands, it is interesting to note that this linker is missing in the prokaryotic HCN homolog MlotiK, in which the CNBD directly modulates the pore 6, 7 . A direct versus indirect coupling of the CNBD to the pore in different cyclic nucleotide gated channels raises the question of whether the C-linker plays in HCN channels a passive or an active role in the transduction of the cAMP signal. It is reasonable to speculate that the increase in structural complexity in eukaryotic HCN channels over the bacterial homolog allowed some additional modes of regulation, which are not present in channels which lack C-linkers. We have now identified a novel binding site, within the C-linker of HCN4, which is part of a mechanism that effectively prevents cAMP activation in this isoform. The C-linker hence adds an additional layer of complexity to provide fine tuning of the activity of the HCN4 channel. Somewhat surprisingly, the lead players of this control mechanism are cyclic dinucleotides, e.g. signaling molecules, which were long believed to function exclusively in bacteria 8 . However after the recent discovery of these molecules in eukaryotes 9 it became evident that they also function as second messengers in metazoa 10, 11 although their known scope of their activity has so far been restricted to the immune system.
Results
The native I f current is modulated by cAMP and, albeit with a lower affinity, also by cGMP 12 . In order to understand the molecular details of the interaction of cGMP with its binding site in the CNBD, we solved the structure of the C-linker and CNBD (CL-CNBD) of HCN4, the main isoform of the cardiac pacemaker 13 , in complex with cGMP. The structure unexpectedly showed two bound cGMP molecules per monomer. The first cGMP was located in the "canonical" CNBD binding site 4 while the second was found at the interface between the C-linker and the CNBD, in what we refer to as the C-linker pocket (CLP) (Fig.1a,b) . In all four HCN4 protomers of the crystal asymmetric unit, a cGMP molecule was modeled in the electron density at the CLP and the structure was successfully refined at 2.7Å resolution, with full atomic occupancy and average B factors comparable to those of adjacent protein residues (Supplementary Table 1) . Notably, no electron density was present in the CLP for crystals grown in the presence of cAMP 14 . The CLP-bound cGMP molecule is in a syn conformation and, by interacting with residues of helix B', B'-C' linker and helix C', bridges the "elbow" and the "shoulder" domain of each subunit 4 . In addition, it interacts with strand 8 of the CNBD (Fig.1c , Supplementary Table 2a) . Moreover, several items of structural evidence of cGMP selectivity were found: the hydrogen bond between F564 amide (main chain) nitrogen and oxygen O6 of c-GMP would not be possible because in cAMP oxygen O6 is replaced by an amino group (N6); the polar contact between the residue Y559 and the N2 nitrogen atom, can only occur with cGMP since the cAMP molecule lacks that atom. CyclicGMP was not observed in the CLP of HCN1 (our unpublished results) and HCN2 4 despite conservation of the residues that directly interact with the molecule. Alignment of the three sequences ( Supplementary Fig.1 ) highlights the occurrence of several amino acid substitutions in the CLP region that can result in a different local structure of the CLP. Superposition of the C chains among HCN isoforms indeed reveals a marked mismatch in the C backbone of the C'-and D'-helices in HCN4 relative to HCN1/HCN2, both in the cGMP and in the cAMP bound forms (Supplementary Fig. 2a and 2b ).
In spite of structural evidence for binding, application of cGMP to HCN4 channels expressed in HEK293T cells did not exhibit any effect on channel function that could be related to occupancy of the CLP. Addition of cGMP to inside-out patches increased HCN4 currents and shifted the voltage for half maximal activation (V 1/2 ) towards positive values ( Supplementary Fig. 3a ), an effect that can be attributed to cGMP binding to the canonical CNBD site. In fact the cGMP binding mode to this pocket matches that of other HCN isoforms (Supplementary Fig. 2c and Supplementary Table 2b ). Hill-plot fitting of the dose-response curve yields values of 13.2 M for half maximal concentration (k 1/2 ), and 0.72 for the Hill coefficient (n) ( Supplementary   Fig. 3b ), which are quite similar to previously reported values for I f 12 . Furthermore, application of cGMP at > 2.5 mM, e.g. concentrations used for crystallization, did not reveal a second component in Hill plots that could be attributed to a secondary binding site ( Supplementary Fig. 3c,d ).
After excluding a functional relevance of cGMP binding to the CLP, further analysis revealed that the pocket is sufficiently wide and accessible to bind a molecule about twice the size of cGMP (Fig.1d) . Since recent studies identified cyclic di-(3',5')-guanosine monophosphate (c-di-GMP, Supplementary Fig. 4 ) as a second messenger in eukarya 9,11 , we tested c-di-GMP binding to the CLP of HCN4 via molecular docking simulation. One of the best docking poses in terms of estimated free energy of binding showed one sugar ring/nucleotide moiety of the c-di-GMP occupying a similar position (although with a slightly different orientation) as the CLP-bound cGMP in the crystal structure, with the second half of the docked molecule being docked in the charged surface cleft (Fig. 1e,f) . Functional tests on HCN4 currents showed a striking result. While addition of c-di-GMP (100 M) in the pipette did not affect the voltage-dependence of HCN4
currents measured in whole cell, the activation curve in the presence of c-di-GMP being indistinguishable from the control (Fig. 2a) , completely opposite results were obtained in the presence of cAMP (15 M). In this case, c-di-GMP completely reversed (i.e. back-shifted) the positive shift of 18 mV induced by saturating cAMP on the activation curve (Fig. 2b, Supplementary Fig. 5a,b) . Figure 2c shows the back shift (in mV) as a function of c-di-GMP concentrations. Hill-plot fitting yielded values of 1.8 µM for k 1/2 and 1.2 for n. To confirm the direct action of c-di-GMP, we tested the molecule in the inside-out configuration (Fig. 2d) .
Addition of c-di-GMP (100 M) instantaneously and efficiently inhibited the increase in current induced by cAMP, fully reversing the shift of 17 mV induced by cAMP on V 1/2 (inset). Raising the cAMP concentration to 1 mM did not change the effect of c-di-GMP on current and activation curve ( Supplementary Fig. 5c,d ).
This excludes competition of the two molecules for the same binding pocket. Indeed, attempts to dock c-di-GMP into the cAMP-free "canonical" pocket in the CNBD of HCN4 indicated no binding, probably because of the excessive size c-di-GMP. In order to exclude the possibility that the effect of c-di-GMP is mediated by the interaction with its known receptor STING 11 , we confirmed by western blot that our heterologous expression system, HEK293T cells, does not express STING protein at detectable levels, neither in basal conditions nor when transfected with HCN4 channels (Supplementary Figure 6a) . Moreover, as an additional control, we checked whether the effect of c-di-GMP on HCN4 currents was cAMP-specific. To this end, we To confirm specific binding of c-di-GMP to the CLP, we searched for site-directed mutations that would abolish or alter the c-di-GMP effect. We selected four key residues (Y559, F564, E566, R680), which line the pocket occupied by the sugar ring/nucleotide moiety of both the cGMP in the crystal structure and of the docked c-di-GMP (Fig. 1c,e) . Mutation of any one of these four residues altered the channel response to c-di-GMP, as shown by the values of V 1/2 measured in control, cAMP and cAMP + c-di-GMP (Figure 2e ). In particular the HCN4 R680E single site mutant proved totally insensitive to c-di-GMP, while its other properties (basal position of V 1/2 and cAMP-induced shift) remained undistinguishable from wt. This phenotype strongly supports the specific interaction of c-di-GMP with the CLP, ruling out the possibility that c-di-GMP binds to the canonical cyclic nucleotide binding site in the CNBD. In addition, we tested on the wt channel the effect of two control substances, Guanosine-5'-triphosphate (GTP, 1 mM) and G5'-Phosphoguanylyl-(3' − 5')-guanosine (pGpG) (100 M), respectively the precursor and the first metabolic degradation product of c-di-GMP. No effect on the cAMP-induced shift was observed in both cases (data not shown), confirming that the HCN4 pocket is rather specific for c-di-GMP.
Docking experiments showed that c-di-GMP would not bind to other isoforms e.g. HCN1 and HCN2.
Although the predicted binding pocket has a high sequence homology, the difference in orientation of E566 (HCN4 numbering) may be a key factor in preventing binding of c-di-GMP to HCN1 and 2 because of a potential steric clash between this residue making and of the phosphate groups of c-di-GMP (Supplementary Figure YY) . When c-di-GMP was tested at saturating concentration on human HCN1 and HCN2 channels expressed in HEK293T cells (Fig. 2f) , neither of the two channels were affected, confirming that the CLP is specific for the HCN4 isoform.
We next tested other cyclic dinucleotides on HCN4: the bacterial c-di-AMP 8 (cyclic di-(3',5')-adenosine monophosphate), and two linkage isomers of cyclic GMP-AMP (cGAMP), the bacterial 3'3'-cGAMP Fig. 2f and Supplementary Fig. 7 ).
We have extended the analysis on 2'3'-cGAMP, since this is, so far, the only cyclic dinucleotide known to be synthesized by mammals. Molecular docking simulation of 2'3'-cGAMP to HCN4 predicted the dinucleotide would bind in the same pocket as c-di-GMP but in a slightly different orientation. However it would still make interactions with the same key residues as identified for c-di-GMP (Supplementary Figure 8a) . When we determined the dose-response curve of the effect of 2'3'-cGAMP on HCN4 currents (Supplementary Figure 8b) , we found a k 1/2 value of 114 nM, which is about 16 times lower than that for c-di-GMP.
Interestingly, the same difference in affinity, nanomolar for the mammalian 2'3'-cGAMP vs. micromolar for the bacterial c-di-GMP has also been reported for STING.
In conclusion, our findings point to a general mechanism whereby cyclic dinucleotides, either endogenous or exogenous, would act as allosteric regulators of the human HCN4 pacemaker channel. Since HCN4 is the main HCN isoform expressed in the cardiac pacemaker 13 , we next tested the effect of cyclic dinucleotides on the native I f current recorded in myocytes acutely isolated from mouse SAN (Fig. 3a) . and a 29% decrease in heart rate from the control of 6.7 ± 0.8 Hz (n = 4) to 4.7 ± 0.3 Hz (n = 5) (P < 0.05) ( Fig. 4d ) correspond to the effects of physiological concentrations of acetylcholine (about 30 nM) 17 .
Next we set up a search for synthetic molecules, which would bind HCN4 CLP and modulate channel function. To this aim we exploited libraries of low molecular weight compounds through in silico screening.
Eleven compounds, structurally unrelated to cyclic dinucleotides, were selected for their high predicted 4d,e) indeed altered the response of HCN4 to C11, supporting the prediction that C11 binds in the CLP (Fig. 4f ). C11 did not affect human HCN2 channels expressed in HEK293T cells (Fig.4f) , confirming that the CLP is specific of the HCN4 isoform.
When tested on the native I f current in the absence and in the presence of cAMP (Figure 4g ), C11 shifted V 1/2 of I f negative by 5.9 mV ( (shift = 0.3 mV). Again, when tested on the activity of single SAN cells, C11 decreased the spontaneous rate of single SAN cells by 30% (from the control of 7.6 ± 0.4 (n = 7) to 5.4 ± 0.5 Hz (n = 6) (P < 0.05)) ( Fig. 4i) , effectively mimicking the action of endogenous acetylcholine on heart rate.
Discussion
The combination of structural, biochemical and functional data reported here shows that the C-linker of HCN4 hosts a regulatory binding site, the CLP, which controls the effect of cAMP on channel open probability. This mechanism is specific for HCN4 and not effective in HCN1 and HCN2. Since HCN4 is the main isoform of the cardiac I f , occupancy of CLP by ligand molecules indeed prevents -adrenergic stimulation on the native current, mimicking the physiological effect of acetylcholine. Even though the control of the responsiveness of HCN channels to cAMP in the heart is reported here for the first time, a down regulation of the cAMP effect seems to be a general requirement for fine-tuning of HCN channel activity. In the brain, where these channels control neuronal excitability and information processing, their response to cAMP is down regulated by the beta subunit TRIP8b 18, 19 ; this cytoplasmic protein co-assembles with HCN channels and inhibits channel opening by antagonizing the effect of cAMP. TRIP8b allosterically competes with cAMP for channel opening and shifts the activation curve to more negative potential; the same allosteric competition occurs when ligands bind to the CLP in HCN4. The modulation by CLP is therefore functionally but not structurally comparable to that of TRIP8b. Since TRIP8b is exclusively expressed in the brain, this modulator is not relevant for the control of cardiac pacemaking activity. The CLP-based mechanism described here, remarkably specific for HCN4, therefore constitutes a relevant way to down regulate the response of I f to cAMP in sinoatrial-node.
The observation that occupancy of the CLP prevents cAMP modulation sheds light on the allosteric coupling between the CNBD and the pore in HCN proteins 5 . Ligand binding to the CLP seems to act as a lock, hampering the movement of the C-linker and preventing the transmission of the conformational change from the CNBD to the pore 5 . The CLP is strategically located between two mobile regions of the C-linker, the "elbow" and "shoulder", a location typically occupied by allosteric effectors in many unrelated proteins.
When the cAMP-bound CNBD initiates the conformational changes leading to channel activation, the ligandbound CLP prevents structural rearrangement therefore favoring the resting configuration of the C-linker.
Mutagenesis analysis further supports the finding that the CLP is located in a crucial position that controls gating properties of the channel. Three out of four mutations introduced in the CLP in this study (Y559T, F564T, E566K), resulted in channels with altered gating properties (altered basal value of V 1/2 and/or altered response to cAMP) (Fig 2e) . The CNBD is known to regulate V 1/2 by exerting a tonic inhibition on the transmembrane pore that is removed by cAMP. Hence the CLP must be in a central position for basal and cAMP-driven control exerted by the CNBD on channel gating. In this context it is worth mentioning that the equivalent mutation of E566K in HCN2 (E515K) has been found in a patient with idiopathic generalized epilepsy 20 . Similarly to that found in HCN4, E515K induces a 30 mV negative shift in the activation curve of HCN2 and a consequent strong reduction of current availability near resting voltages.
The functional significance of the CLP in HCN4 makes this binding site a potential target for the delivery of heart rate control drugs. The high affinity for the CLP shown by Compound 11, which blocks adrenergic stimulation at nanomolar concentrations, proves that it is in principle possible to design an effective drug by in silico docking to the CLP. Because of the isoform-specificity of the CLP such drugs may be attractive alternatives to the less isoform-specific channel pore blockers 21 .
A most unexpected finding is that prokaryotic and eukaryotic cyclic dinucleotides, are potent antagonist of cAMP in HCN4. The interest in cyclic dinucleotides as second messengers in mammals has so far been restricted to the immune system where they initiate the STING-mediated release of interferon in response to the presence of bacterial 10 or viral 22 DNA in the cytoplasm. Since a number of different cyclic dinucleotides are able to regulate HCN4 activity, we cannot exclude the possibility that other endogenous ligands bind to the CLP. Still it is worth noting that the cyclic-GMP-AMP synthase (cGAS) 23 , the key enzyme which produces the mammalian 2'3'-cGAMP, is abundantly expressed in many different tissues including heart 
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Protein preparation
The cDNA fragment comprising the C-linker (CL) and CNBD region of human HCN4 (residues 521-723), was cloned into a modified pET-24b plasmid, transformed into E. coli Rosetta strain, overexpressed and purified as previously described 14 .
Crystallization and structure determination
Crystallization trials were set up in 96-well sitting drop plates (Greiner) using the Orxy 8. 
Constructs
The hHCN4 and hHCN2 complementary DNA was inserted in the eukaryotic expression vector pcDNA 3.1 (Clontech Laboratories). Mutations were generated by site-directed mutagenesis (QuikChange site-directed mutagenesis kit; Agilent Technologies) and confirmed by sequencing.
Electrophysiology of HEK293T cells
Complementary DNA of wild-type and mutant channels was co-transfected for transient expression into 
Western blot
Fifty-percent confluent HEK293TT cells were transfected (in 35 mm diameter wells) respectively with hHCN4 (2ug) and hSTING (2ug) with Lipofectamine2000 reagent (Invitrogen). pMAX-GFP plasmid was co-transfected. Expression of hHCN4 was verified by patch-clamp recordings. After 48hrs, cells were resuspended in PBS pH7.4 supplemented with Triton X-100 1%(v/v) and protease inhibitors cocktail (Complete, Roche). Cells were gently broken with a 27G needle. Cells debris was centrifuged at 8000 xg for 10 minutes at 4°C. The supernatant was collected and analyzed by SDS-PAGE and western blot. For immunodetection STING antibody (Cell Signaling Technology) and anti-rabbit HRP conjugated were used.
Virtual high-throughput screening using eHiTS
The electronic high-throughput screening program eHiTS 40, 41 were fitted to the mean data points (n≥3) and the resulting V 1/2 and s were: c-di-AMP, , -97.1 ± 0.2 mV, 10
